BMY - Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
2025-03-11 16:00:09 ET
Summary
- Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis.
- Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications.
- Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk.
- Future PTGX prospects include expanding icotrokinra's use to Crohn's Disease and initiating phase 1 study for PN-881, targeting immune-mediated disorders like hidradenitis suppurativa.
The last time I spoke about Protagonist Therapeutics, Inc. ( PTGX ) it was in a Seeking Alpha article entitled “ Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck. ” In this article, I noted that the company was gearing up to release results from its ongoing phase 3 VERIFY study using its drug rusfertide to treat patients with polycythemia vera [PV] in Q1 of 2025. I'm pleased to report that not only was the company able to release such data from this late-stage study using this drug to treat these patients, but it was also able to achieve the primary endpoint of it as well....
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It